BLFS - BioLife Solutions, Inc.
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
37%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 59.27%
Operating Income is Negative
Net Income turning Positive
Earnings Per Share (EPS) is Negative but improving
Net Margin is 36.09%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 6.18
Debt Ratio is 0.07
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow is MODERATE
Cash from Operations Growth is 103.24%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
BioLife Solutions, Inc. (BLFS) - http://www.biolifesolutions.com
BioLife Solutions, Inc. engages in the development, manufacture and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Michael P. Rice
Employees - 158
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.